Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease
The overall purpose of this proposed study is to improve management of vaso-occlusive
episodes (VOEs) in adult EDs. We aim to implement NHLBI recommendations for VOE treatment by
embedding Individualized Pain Plans (IPPs) in the electronic health record (EHR). The
...
Age: 18 - 45 years
Gender: All
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body.
MF disturbs the body's normal production of blood cells, causing extensive scarring in the
bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. ...
Age: 18 years - 66+
Gender: All
Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization
This project proposes to develop, test and evaluate targeted interventions to improve
clinical provider prescribing of and patient adherence to hydroxyurea (HU). Using a
stepped-wedge design, The investigators will test two innovative interventions utilizing
mobil...
Age: 15 - 45 years
Gender: All
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation
The purpose of this study is to determine if a search strategy of searching for an HLA-matched unrelated donor for allogeneic transplantation if possible then an alternative donor if an HLA-matched unrelated donor is not available versus proceeding directly to an altern...
Age: Birth - 66+
Gender: All
A Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib With Concomitant Luspatercept for Subjects With Anemia
This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS
(Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary
Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF), or Post-Essenti...
Age: 18 years - 66+
Gender: All
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
Primary Objectives:
To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric
CKD subjects with iron deficiency anemia (IDA) or who are at risk of development of IDA
Secondary Objective:
To determine the single-dose pharmacokinetics ...
Age: 2 - 17 years
Gender: All
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
This is a Phase 2, multicenter, open-label study to evaluate the efficacy and safety of
luspatercept in subjects with MPN-associated myelofibrosis and anemia with and without
RBC-transfusion dependence. The study is divided into a Screening Period, a Treatment Period
...
Age: 18 years - 66+
Gender: All
Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency
The primary objective of this study is to determine the efficacy and safety of iron therapy
using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo, in the treatment of
participants in heart failure with iron deficiency and with a reduced ejection fr...
Age: 18 years - 66+
Gender: All
STRIDE Biorepository
The STRIDE Biorepository is an optional substudy available to participants in "Bone Marrow
Transplantation vs Standard of Care in Patients with Severe Sickle Cell Disease (BMT CTN
1503) (STRIDE)".
Age: 15 - 40 years
Gender: All
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
This study is an access and distribution protocol for unlicensed cryopreserved cord blood
units (CBUs) in pediatric and adult patients with hematologic malignancies and other
indications.
Age: Birth - 66+
Gender: All